CDA | Evidence Driven
CDA | Evidence Driven

upadacitinib

Details

Files
Generic Name:
upadacitinib
Project Status:
Complete
Therapeutic Area:
Crohns disease
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Rinvoq
Project Line:
Reimbursement Review
Project Number:
SR0775-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderately to severely active Crohn’s disease who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least one of conventional and/or biologic therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with moderately to severely active Crohn’s disease who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least one of conventional and/or biologic therapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open16-Mar-23
Call for patient/clinician input closed09-May-23
Clarification:

- Patient input submission received from Crohn’s and Colitis Canada and Gastrointestinal Society

Submission received05-Jun-23
Submission accepted19-Jun-23
Review initiated20-Jun-23
Draft CADTH review report(s) provided to sponsor for comment05-Sep-23
Deadline for sponsors comments14-Sep-23
CADTH review report(s) and responses to comments provided to sponsor13-Oct-23
Expert committee meeting (initial)25-Oct-23
Draft recommendation issued to sponsor06-Nov-23
Draft recommendation posted for stakeholder feedback16-Nov-23
End of feedback period30-Nov-23
Final recommendation issued to sponsor and drug plans14-Dec-23
Final recommendation posted09-Jan-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)05-Jan-24
CADTH review report(s) posted14-Mar-24

Files

Recommendation and Reasons View PDF
Clinical and Pharmacoeconomic combined Report View PDF
Stakeholder feedback on Draft Recommendation View PDF
Last Updated : March 14, 2024